Replies to post #173442 on Biotech Values

[genisi]

If I were MNTA or MYL I would first want to see the FDA approves the 20mg and then how well the generic version sells.

[DewDiligence]

What would stop MNTA or MYL from submitting an ANDA for thrice-weekly [Copaxone] as well (assuming approval of their generic copax of course)?

It would be technically easy; however, it might not be worth the effort, especially if both companies get approval for generic versions of regular Copaxone.